WONDERLAB Officially Announces an Exclusive Strategic Partnership with IFF for China-Bottled B420 Probiotics

On September 24, WONDERLAB and IFF, a global leading probiotic-ingredient company whose probiotic business originated with DuPont Nutrition & Biosciences, renewed their strategic cooperation agreement in Anji, Zhejiang. WONDERLAB officially announced that it is IFF’s exclusive strategic partner in China for B420 probiotics bottled domestically. Jin Su, General Manager of IFF Health Sciences for Asia Pacific; Tao Lu, Director of Strategic Marketing and Product Management; Guoxun Xiao, CEO of WONDERLAB; and Yanchen Liu, WONDERLAB’s Brand Director, attended the event and jointly witnessed the opening of a new chapter in the two companies’ comprehensive strategic cooperation.

WONDERLAB and IFF sign their strategic cooperation agreement

IFF Announces an Exclusive Strategic Partnership to Co-Create Evidence-Based Probiotic Industry Standards

At the signing ceremony, Tao Lu shared his insights into and outlook for the probiotic industry: “The development of probiotics requires the efforts of the entire industry, long-term investment, and a commitment to a science- and evidence-based R&D philosophy in order to create truly good products and better serve consumers.” He noted that the current Chinese probiotic dietary-supplement market presents four areas of opportunity: first, confusing labeling and false advertising; second, inadequate assurance of viability; third, fierce competition and serious homogenization; and fourth, a lack of scientific basis and rigor. These are areas where IFF, WONDERLAB and the entire industry must work together to ensure healthier and more sustainable development.

Tao Lu, IFF’s Director of Strategic Marketing and Product Management

As a global leader in the probiotic industry, IFF has more than a century of experience in probiotic clinical research and serves as a benchmark for industry standard-setting. WONDERLAB and IFF first entered into a strategic partnership in 2021 and established the HOWARU®–WONDERLAB Joint Innovation Center for Probiotics. Over the past three years, the partnership has delivered multiple research outcomes and a range of high-quality products. The renewal of the strategic cooperation agreement marks the two companies’ continued deepening of comprehensive strategic collaboration. Together, they will advance science- and evidence-based standard-setting for the probiotic industry, promote industry development and work to create products that meet the needs of future consumers.

Jin Su, General Manager of IFF Health Sciences, Asia Pacific

Following a Specialized Evidence-Based Pathway, IFF-Originated B420™ Makes Its Debut

At the signing event, WONDERLAB officially launched IFF-Originated B420™ and gave a comprehensive introduction to the evidence-based pathway behind it. Liu Yanchen, WONDERLAB’s Brand Director, explained that IFF-Originated B420™ is Bifidobacterium lactis B420, researched and discovered by IFF, supplied through IFF’s strategic partnership and imported in its original form. IFF-Originated B420™ offers consumers three layers of assurance. First, every B420™ strain is 100% imported from IFF and added at the full stated amount, preserving its authentic provenance. Second, every B420™ strain has undergone scientific efficacy research and verification, supported by patents in multiple countries, 273 publications and 98 global experimental validations. Third, every B420™ strain has a publicly traceable genome map, helping ensure genetic continuity and consistency, stable characteristics without variation, and safety.

WONDERLAB’s IFF-Originated B420™ launch event

IFF has conducted nearly 20 years of continuous research on the B420 strain and is widely recognized across the global industry as an authority and quality leader. At the event, Jin Su shared clinical data and said: “IFF has conducted nearly 20 years of continuous research on the B420 strain. HOWARU® B420 is not only a weight-management specialist but also an MVP for metabolic health.”

Regarding the renewed cooperation, Liu Yanchen said at the event: “WONDERLAB is honored to have reached another strategic partnership with IFF. By combining WONDERLAB’s full industrial-chain capabilities with IFF’s professional expertise and market influence in probiotics, the two companies can secure stronger scientific-research support and market assurance for their development. We also look forward to working together with IFF to advance the healthy development of the probiotic industry and bring consumers more scientific and effective health solutions.”

IFF announces its exclusive strategic partnership with WONDERLAB

WONDERLAB also officially announced that cumulative sales of its probiotic products had exceeded 500 million bottles, reaching a new record and once again demonstrating its leading position in the industry. Going forward, WONDERLAB will continue to focus on science- and evidence-based R&D standards, provide consumers with high-quality products and health services, and work with upstream and downstream partners across the industry to promote its development.